Lipid Binding Proteins in Obesity and Diabetes Syndromes
Lipid Binding Proteins in Obesity and Diabetes Syndromes
批准号:
9924511
负责人:
David A Bernlohr
金额:
$38.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-12 至 2022-05-31
关键词:
AdipocytesAdipose tissueAffectAnimal ModelAnimalsAnti-Inflammatory AgentsAsthmaAttenuatedBeta CellBindingBinding ProteinsBiologyCardiovascular DiseasesCellsCeramidesCharacteristicsDevelopmentDiabetes MellitusDiseaseDrug TargetingEndocrineEquilibriumEventExhibitsFABP4 geneFatty AcidsFatty acid glycerol estersFundingGenetic PolymorphismHeart HypertrophyHigh Fat DietHumanHyperlipidemiaHypertensionHypertriglyceridemiaImmuneImpairmentInflammasomeInflammationInflammatoryInsulin ResistanceKnock-outKnockout MiceLaboratoriesLeukotrienesLinkLipid BindingLipidsLipolysisLiverMediatingMetabolicMetabolic DiseasesMetabolic syndromeMetabolismMitochondriaMitochondrial ProteinsMolecularMolecular ChaperonesMolecular GeneticsMonounsaturated Fatty AcidsMusNon-Insulin-Dependent Diabetes MellitusNonesterified Fatty AcidsObesityOxidative StressPharmacologyPhenotypePhysiologicalPlayPredispositionProteinsPyruvateReactive Oxygen SpeciesRegulationRiskRoleSIRT1 geneSecond Messenger SystemsSignal InductionSyndromeTNF geneTestingTherapeuticThrombosisUCP2 proteinUp-RegulationVisceralWorkadiponectinbasebreast cancer progressionendoplasmic reticulum stressendothelial dysfunctionepigenomefatty acid-binding proteinsgain of functionimprovedinsulin secretioninsulin sensitivitylipid metabolismmacrophagemitochondrial dysfunctionmitochondrial metabolismneuroinflammationnoveloverexpressionoxidationpromoterresponsesmall molecule
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Molecular and physiological studies have revealed that inflammation of adipose tissue is a key determinant in the development of the metabolic syndrome and a variety of animal models have been utilized to identify mechanisms that link adipocytes and macrophages to disease. Of these, the Fatty Acid Binding Protein 4 (FABP4, also known as aP2) loss/gain mouse has been particularly insightful in developing our current understanding of inflammation, ER stress, mitochondrial dysfunction and metabolic disease. Fatty acid binding proteins are intracellular FFA chaperones found expressed at high levels in adipocytes and macrophages. Surprisingly, when placed on high fat diets, FABP4 knockout mice exhibit attenuated characteristics of the metabolic syndrome including diminished lipolysis, reduced TNFα and increased adiponectin expression, improved insulin sensitivity, decreased NF-κB activation, protection from asthma, diminished atherogenic capacity and attenuate neuroinflammation. In contrast, mice over-expressing FABP in adipose tissue exhibit potentiated characteristics of the metabolic syndrome including increased lipolysis, exacerbated insulin resistance, decreased adiponectin secretion, and mild cardiac hypertrophy. Similar to the animal models, humans with decreased adipocyte FABP (arising via a polymorphism in the FABP4/aP2 promoter) exhibit reduced risk for hypertriglyceridemia, type 2 diabetes and cardiovascular disease. During the last funding cycle the laboratory has identified a novel FABP4-SirT1-UCP2 axis that regulates lipid metabolism in macrophages and adipocytes. Briefly, molecular, genetic or pharmacologic loss of FABP leads to increased cellular fatty acids and a cascade of events linked to SirT1 activation and the up regulation of UCP2. Increased expression of UCP2 enables increased β-oxidation of FFA, attenuates pyruvate entry into the mitochondrion, reduces the level of reactive oxygen species and oxidative stress. Diminished ROS reduces mitochondrial protein oxidation, the mitochondrial Unfolded Protein Response (mtUPR), activation of NF-κB signaling, and induction of the inflammasome. The central hypothesis for this application is that the FABP4-FFA equilibrium controls activation of SirT1 and subsequently UCP2 expression in macrophages. Moreover, up regulation of UCP2 is both necessary and sufficient to shift immune cells of high fat fed mice from a classically activated pro-inflammatory M1 phenotype to the alternatively activated anti-inflammatory M2 form. To test this hypothesis, the following specific aims are proposed: Aim 1. Evaluate the regulation of SirT1 by fatty acids and its control by FABP4. Aim 2. Examine cellular metabolism and polarization of cultured macrophages stably overexpressing UCP2. Aim 3. Evaluate the metabolic effects of macrophage-specific knockout and overexpression of UCP2 in experimental mice.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Interaction of adipocyte fatty acid-binding protein (AFABP) and JAK2: AFABP/aP2 as a regulator of JAK2 signaling.
脂肪细胞脂肪酸结合蛋白 (AFABP) 和 JAK2 的相互作用:AFABP/aP2 作为 JAK2 信号传导的调节剂。
DOI:
10.1074/jbc.m900075200
发表时间:
2009
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
[Thompson,BrianR, Mazurkiewicz-Muñoz,AnnaM, Suttles,Jill, Carter-Su,Christin, Bernlohr,DavidA]
通讯作者:
Bernlohr,DavidA
Fatty acid transport in adipocytes and the development of insulin resistance.
脂肪细胞中的脂肪酸转运和胰岛素抵抗的发展。
DOI:
10.1002/9780470985571.ch10
发表时间:
2007
期刊:
Novartis Foundation symposium
影响因子:
--
作者:
[Lobo,Sandra, Bernlohr,DavidA]
通讯作者:
Bernlohr,DavidA
DOI:
10.1038/nrendo.2015.122
发表时间:
2015-10
期刊:
Nature reviews. Endocrinology
影响因子:
--
作者:
[Hotamisligil GS, Bernlohr DA]
通讯作者:
Bernlohr DA
DOI:
10.1038/labinvest.2009.33
发表时间:
2010-06
期刊:
Laboratory investigation; a journal of technical methods and pathology
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.4049/jimmunol.0804192
发表时间:
2009-06-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J]
通讯作者:
Suttles J
共 7 条
Midwest Murine-Tissue Mapping Center (MM-TMC)
-
批准号:10552986
-
项目类别:
-
资助金额:$270.0万
-
财政年份:2022
-
负责人:David A Bernlohr
-
依托单位:
Midwest Murine-Tissue Mapping Center (MM-TMC)
-
批准号:10675007
-
项目类别:
-
资助金额:$270.0万
-
财政年份:2022
-
负责人:David A Bernlohr
-
依托单位:
Administrative Core
-
批准号:10675008
-
项目类别:
-
资助金额:$72.07万
-
财政年份:2022
-
负责人:David A Bernlohr
-
依托单位:
Administrative Core
-
批准号:10552987
-
项目类别:
-
资助金额:$50.71万
-
财政年份:2022
-
负责人:David A Bernlohr
-
依托单位:
Inflammation, Lipid Metabolism and Senescence
-
批准号:10264042
-
项目类别:
-
资助金额:$38.59万
-
财政年份:2020
-
负责人:David A Bernlohr
-
依托单位:
Inflammation, Lipid Metabolism and Senescence
-
批准号:10661613
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2020
-
负责人:David A Bernlohr
-
依托单位:
Inflammation, Lipid Metabolism and Senescence
-
批准号:10432085
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2020
-
负责人:David A Bernlohr
-
依托单位:
Inflammation, Lipid Metabolism and Senescence
-
批准号:10094457
-
项目类别:
-
资助金额:$37.01万
-
财政年份:2020
-
负责人:David A Bernlohr
-
依托单位:
Molecular and Cellular Basis of Obesity Core
-
批准号:8132707
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2011
-
负责人:David A Bernlohr
-
依托单位:
Mitochondrial Dysfunction and Adipose Insulin Resistance
-
批准号:8531229
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2010
-
负责人:David A Bernlohr
-
依托单位:
Mitochondrial Dysfunction and Adipose Insulin Resistance
-
批准号:7893525
-
项目类别:
-
资助金额:$37.41万
-
财政年份:2010
-
负责人:David A Bernlohr
-
依托单位:
Mitochondrial Dysfunction and Adipose Insulin Resistance
-
批准号:8706849
-
项目类别:
-
资助金额:$31.07万
-
财政年份:2010
-
负责人:David A Bernlohr
-
依托单位:
Mitochondrial Dysfunction and Adipose Insulin Resistance
-
批准号:8298244
-
项目类别:
-
资助金额:$31.07万
-
财政年份:2010
-
负责人:David A Bernlohr
-
依托单位:
Mitochondrial Dysfunction and Adipose Insulin Resistance
-
批准号:8059616
-
项目类别:
-
资助金额:$31.07万
-
财政年份:2010
-
负责人:David A Bernlohr
-
依托单位:
Mitochondrial Dysfunction and Adipose Insulin Resistance
-
批准号:7847293
-
项目类别:
-
资助金额:$18.54万
-
财政年份:2009
-
负责人:David A Bernlohr
-
依托单位:
Lipid Binding in Obesity/Diabetes Syndromes
-
批准号:7996303
-
项目类别:
-
资助金额:$9.78万
-
财政年份:2009
-
负责人:David A Bernlohr
-
依托单位:
Obesity and Energy Metabolism Core
-
批准号:7120310
-
项目类别:
-
资助金额:$16.63万
-
财政年份:2006
-
负责人:David A Bernlohr
-
依托单位:
Lipid Binding in Obesity/Diabetes Syndromes
-
批准号:7322863
-
项目类别:
-
资助金额:$29.94万
-
财政年份:1998
-
负责人:David A Bernlohr
-
依托单位:
Lipid Binding in Obesity/Diabetes Syndromes
-
批准号:7638529
-
项目类别:
-
资助金额:$29.81万
-
财政年份:1998
-
负责人:David A Bernlohr
-
依托单位:
Lipid Binding in Obesity/Diabetes Syndromes
-
批准号:7998840
-
项目类别:
-
资助金额:$7.87万
-
财政年份:1998
-
负责人:David A Bernlohr
-
依托单位:
海外基金